Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Haematopoietic stem cell therapy - Lineage Cell Therapeutics

Drug Profile

Haematopoietic stem cell therapy - Lineage Cell Therapeutics

Alternative Names: Haematological disorders-hESC therapy - Geron; Haematological disorders-hESC therapy - Lineage Cell Therapeutics

Latest Information Update: 06 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Geron Corporation
  • Developer Asterias Biotherapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Bone marrow disorders; Haematological disorders

Most Recent Events

  • 31 Jul 2019 BioTime is now called Lineage Cell Therapeutics
  • 11 Mar 2019 Asterias Biotherapeutics has been acquired and merged into BioTime
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bone-marrow-disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top